ロード中...
Further analysis of PREVAIL: enzalutamide use in chemotherapy-naïve men with metastatic castration-resistant prostate cancer
PREVAIL was a phase III multinational, double-blind, placebo-controlled trial that enrolled chemotherapy-naïve men with metastatic castration-resistant prostate cancer (mCRPC), which showed remarkable improvement in co-primary endpoints with an overall 81% reduction in the risk of radiographic progr...
保存先:
| 出版年: | Asian J Androl |
|---|---|
| 第一著者: | |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Medknow Publications & Media Pvt Ltd
2014
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4236317/ https://ncbi.nlm.nih.gov/pubmed/25080931 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/1008-682X.135129 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|